Partner Reed Kathrein Scrutinizing ZBH's "High Confidence" Assurances After 15% Stock Collapse and Reduced Revenue Guidance SAN FRANCISCO, Jan. 27, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is investigating Zimmer Biomet Holdings, Inc. (NYSE: ZBH) following a series of disclosures that calls into question the reasonable basis for the company's previously expressed "high confidence" in its 2025 revenue targets. The firm urges investors who suffered significant losses to submit ...

SAN FRANCISCO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is investigating Zimmer Biomet Holdings, Inc. (NYSE: ZBH) following a series of disclosures that calls into question the reasonable basis for the company’s previously expressed “high confidence” in its 2025 revenue targets. The firm urges investors who suffered significant losses to submit your ZBH losses now and visit Hagens Berman’s case page to view our latest investigation summary: www.hbsslaw.com/cases/z ...

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is included on our list of the best undervalued wide moat stocks. Zimmer Biomet Holdings (ZBH)'s 2026 Expectations Remain Cautious Amid Internal Reset On January 13, 2026, Zimmer Biomet Holdings, Inc. (NYSE:ZBH) laid out cautious expectations for 2026 at the 44th Annual J.P. Morgan Healthcare Conference, according to The Fly. While we don’t have specific details at this time, the company said its guidance will reflect the scale of the internal changes it has planne ...

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is included on our list of the best undervalued wide moat stocks. Zimmer Biomet Holdings (ZBH)'s 2026 Expectations Remain Cautious Amid Internal Reset On January 13, 2026, Zimmer Biomet Holdings, Inc. (NYSE:ZBH) laid out cautious expectations for 2026 at the 44th Annual J.P. Morgan Healthcare Conference, according to The Fly. While we don’t have specific details at this time, the company said its guidance will reflect the scale of the internal changes it has planne ...

Core Viewpoint - The article discusses the potential of undervalued wide moat stocks as U.S. markets transition into 2026, highlighting a shift in macroeconomic conditions that may favor small-cap stocks due to expected earnings growth and easing interest rates [1][2]. Market Outlook - Analysts predict two 25-basis-point rate cuts by the Federal Reserve in 2026, which could benefit small-cap companies with high debt levels [3]. - The Russell 2000 index is expected to rise to 2,825 by the end of 2026, indicating a projected gain of approximately 14% from 2025 levels [3]. Sector Analysis - Healthcare and financial sectors are identified as key beneficiaries of favorable policies, M&A activity, and AI-related efficiency improvements [5]. - The banking segment is projected to outperform in 2026, prompting investors to seek stocks with strong fundamentals and competitive positioning [5]. Investment Methodology - The analysis utilizes the VanEck Morningstar Wide Moat ETF to identify undervalued stocks, filtering for those trading at least 25% below the S&P 500's forward P/E of 22.34 as of January 16, 2026 [7]. - Hedge fund sentiment is considered, with a focus on stocks held by a significant number of hedge funds, as this strategy has historically outperformed the market [8]. Company Highlights - **Zimmer Biomet Holdings, Inc. (NYSE:ZBH)**: - Forward P/E of 10.27x with 35 hedge fund holders; cautious expectations for 2026 were communicated at the J.P. Morgan Healthcare Conference [10][11]. - Management revised 2025 organic revenue growth forecast down to 4.00% from 4.50% due to weaker demand in certain regions, but overall revenue growth estimates remained stable [12]. - **Huntington Bancshares Incorporated (NASDAQ:HBAN)**: - Forward P/E of 10.60x with 42 hedge fund holders; RBC Capital raised its price target from $20.00 to $21.00, citing stable fundamentals and a positive outlook [15][16]. - The company is set to merge with Cadence Bank, expected to enhance capabilities and shareholder value [17]. - **Masco Corporation (NYSE:MAS)**: - Forward P/E of 16.67x with 44 hedge fund holders; Wells Fargo raised its price target from $75.00 to $78.00, while RBC Capital lowered its target from $69.00 to $67.00, reflecting mixed outlooks in the building products sector [19][20][21].

Core Viewpoint - Zimmer Biomet Holdings, Inc. will host its fourth quarter earnings conference call on February 10, 2026, at 8:30 a.m. ET, with a news release detailing the quarterly results available at 6:30 a.m. ET on the same day [1]. Group 1: Earnings Call Details - The earnings conference call will be accessible via a live audio webcast on Zimmer Biomet's Investor Relations website, with a replay available after the call [2]. - U.S. and Canada participants can join the call by dialing (800) 330-6710, while international callers should use +1 (213) 279-1505, both requiring conference ID 7090861 [2]. Group 2: Company Overview - Zimmer Biomet is recognized as a global leader in medical technology, offering a comprehensive portfolio aimed at enhancing mobility and health [3]. - The company focuses on transforming patient experiences through innovative products and integrated digital and robotic technologies that utilize data analytics and artificial intelligence [3]. - With over 90 years of experience, Zimmer Biomet is committed to delivering high-quality solutions to patients and healthcare providers, reflecting a culture of evolution and innovation [4].

Core Insights - The JPM Health Conference highlighted a shift in focus among major medical device companies from investment narratives to growth execution, emphasizing the importance of mergers and acquisitions, AI integration, and organizational restructuring for future growth [2][4]. Medtronic - Medtronic's leadership emphasized a transition to a "growth execution phase," with a focus on accelerating growth through existing technologies and strategic acquisitions, particularly smaller tuck-in acquisitions [6][7]. - The company plans to launch its Hugo surgical robot system in the U.S. in 2026, targeting soft tissue surgery as a key growth area, and sees significant market potential in cardiac electrophysiology and renal denervation [7][8]. - Medtronic aims for mid-to-high single-digit revenue growth in 2026, driven by advancements in ASC penetration and AI-enabled surgical planning [8]. Boston Scientific - Boston Scientific reported over 10% revenue growth for three consecutive years, driven by core products like PFA and WATCHMAN, with a focus on maintaining high growth in the electrophysiology market [10][11]. - The company aims to enhance the overall adoption of arrhythmia treatments and expand its product offerings, including the FARAPOINT catheter, to new indications [11]. - Boston Scientific's growth strategy includes targeting outpatient surgical centers and advancing its clinical pipeline with new innovations [11]. Stryker - Stryker's CEO highlighted the importance of mergers and acquisitions, particularly in orthopedics and neurology, while focusing on enhancing the Mako robotic platform [12][14]. - The company expects to achieve 7%-9% revenue growth in 2026, with a strong emphasis on outpatient surgical centers as a significant growth driver [14]. Johnson & Johnson - Johnson & Johnson's CEO indicated a return to fundamentals, with a focus on execution and long-term growth, planning to invest approximately $55 billion in new facilities and R&D, particularly in MedTech [15][17]. - The company is preparing for regulatory milestones for its Ottava surgical robot system, with significant contributions expected post-2028 [17][18]. - J&J's strategy includes strategic investments in robotic systems to enhance its outpatient surgical capabilities [18]. Intuitive Surgical - Intuitive Surgical's focus remains on expanding its da Vinci system and integrating AI functionalities to improve surgical efficiency [19][20]. - The company anticipates a competitive landscape in soft tissue robotics but believes its established ecosystem provides a competitive advantage [20]. - Intuitive expects revenue growth of 12%-15% in 2026, driven by increased surgical volumes and international market expansion [20]. Alcon - Alcon is committed to innovation in eye health, focusing on surgical and vision care segments, with a significant emphasis on enhancing operational efficiency [22][23]. - The company aims to launch 10-15 new products over the next two years, maintaining an annual R&D investment of around $1 billion [23]. Abbott - Abbott's strategy emphasizes stable execution, particularly in diabetes management, with plans to expand the FreeStyle Libre system's applications [24]. - The company expects 8%-10% revenue growth in its MedTech business for 2026, focusing on internal innovation and operational efficiency [24]. GE Healthcare - GE Healthcare is shifting its AI capabilities towards standalone software tools, emphasizing the commercialization of AI in imaging [25]. - The company plans to simplify its product offerings to enhance customer experience and reduce internal costs, aiming for organic growth through advanced imaging technologies [25]. Illumina - Illumina's growth strategy focuses on sequencing, multi-omics, and scaling services, with a strong emphasis on partnerships to accelerate drug development [29][30]. - The company aims to maintain a balanced approach between innovation investment and shareholder returns, with a positive outlook for the Chinese market [30]. Edwards Lifesciences - Edwards Lifesciences is focused on structural heart disease, with a commitment to innovation in TAVR and TMTT platforms, expecting 8%-10% sales growth [33][34]. - The company is addressing regulatory challenges while continuing to invest in breakthrough therapies and expanding market access [34]. Jabil - Jabil's CEO discussed the company's transformation and focus on integrating recent acquisitions, with a strategic emphasis on improving sales efficiency in the U.S. market [36][37]. - The company plans to launch new products and leverage AI technology to enhance its offerings in the orthopedic sector [37]. Conclusion - The overall sentiment from the JPM26 conference indicates that major medical device companies are prioritizing alignment of products, organizational structure, and capital utilization to drive growth, rather than focusing solely on new technologies [40].

Group 1 - The presentation is led by Ivan Tornos, who is the President, CEO, and Chairman of the Board of Zimmer Biomet [1] - The company aims to summarize its presentation quickly to accommodate the busy schedule of the audience, which includes numerous presentations over the next few days [2] - Zimmer Biomet expresses satisfaction with the progress made over the last five years, indicating a positive outlook for the company in 2026 [3]

Summary of Zimmer Biomet FY Conference Call (January 13, 2026) Company Overview - **Company**: Zimmer Biomet (NYSE: ZBH) - **Industry**: Medical Technology (MedTech), specifically Orthopedics Key Points and Arguments Company Transformation and Growth - Zimmer Biomet has undergone significant transformation over the past five years, shifting from a product-focused to a solutions-oriented approach, with an emphasis on cultural change [4][5] - The company reported a Compound Annual Growth Rate (CAGR) of 6.5% over the last five years, with revenue growth of 10% in 2021, 6.5% in 2022, and 7.5% in 2023 [5][6] - Adjusted earnings per share (EPS) for 2023 was $9.50, with a leverage of 200 basis points [5] U.S. Market Focus - The U.S. market accounts for 63% of Zimmer Biomet's revenue and over 51% of its debt [7] - The company aims to accelerate the transformation of its sales model in the U.S. to improve accountability and ownership [6][7] - A significant change in the U.S. sales model is planned, with a focus on specialization and direct sales [22] Innovation and Product Development - The company has shifted from launching eight products in 2018 to over 50 new products in the last three years, with 22 launched in 2025 alone [10][11] - Key innovations include the introduction of the first iodine-coated device aimed at preventing infections, set to launch in Japan in late 2025 [17][18] - The company is focusing on customer-centric innovation, addressing issues such as infection, efficiency, and patient outcomes [20][31] Market Dynamics - The orthopedic market is projected to grow at a rate of 4% to 4.25%, with Zimmer Biomet's performance tied to maintaining growth above this benchmark [13] - The company has seen consistent price positivity over the last seven quarters, indicating a favorable pricing environment [42] Financial Outlook - The company expects free cash flow to grow by 70% over the next five to six years, with 2026 anticipated to see free cash flow growth outpacing EPS growth [27][56] - Guidance for 2026 is tempered, aligning with the level of transformation expected, with projected organic growth of 3.5% to 4% [35][36] Strategic Investments - Zimmer Biomet has made three acquisitions in the past 14 months, including OrthoGrid and Paragon 28, to enhance its product offerings and market position [27][28] - The company plans to significantly increase its workforce dedicated to robotic solutions and ASCs (Ambulatory Surgery Centers) [24][25] Challenges and Execution - The company acknowledges the need for improved execution to ensure steady growth, addressing past inconsistencies in quarterly performance [20][21] - The transition to a specialized sales force is expected to create short-term disruptions but aims for mid- to long-term growth acceleration [46] Future Vision - By 2030, Zimmer Biomet aims to innovate beyond traditional implants, focusing on cartilage repair and leveraging data for predictive analytics in orthopedic care [32][33][34] Additional Important Insights - The company has improved employee engagement, making it to Forbes' World's Best Employers list for the first time [11] - Zimmer Biomet is committed to building a best-in-class company, focusing on operational excellence, innovation, and a strong company culture [30][34] This summary encapsulates the key points discussed during the conference call, highlighting Zimmer Biomet's strategic direction, market dynamics, and future aspirations in the orthopedic industry.

Core Viewpoint - Zimmer Biomet Holdings, Inc. is facing challenges with sales growth and operational expenses, leading to a cautious outlook despite expected earnings growth in the upcoming quarters [5][6]. Financial Performance - The company is expected to report an adjusted EPS of $2.38 for fiscal Q4 2025, reflecting a 3% increase from $2.31 in the same quarter last year [2]. - For fiscal 2025, analysts predict an adjusted EPS of $8.16, a 2% rise from $8 in fiscal 2024, with further growth projected to $8.41 in fiscal 2026, representing a 3.1% year-over-year improvement [3]. Stock Performance - Zimmer Biomet's shares have declined by 12.5% over the past 52 weeks, underperforming the S&P 500 Index, which increased by 19.7%, and the Health Care Select Sector SPDR Fund, which rose by 12.7% during the same period [4]. - The stock's underperformance is attributed to disappointing sales growth, lowered guidance, competitive pressures, and operational challenges [5]. Analyst Sentiment - The consensus rating for Zimmer Biomet stock is a "Hold," with 26 analysts covering the stock: six recommend a "Strong Buy," one a "Moderate Buy," 16 a "Hold," and three a "Strong Sell" [6]. - The average analyst price target for Zimmer Biomet is $102.73, indicating a potential upside of 12.3% from current levels [6].